I
ntegrins are major cell adhesion molecules, mediating cell-cell and cell-extracellular matrix interactions. Integrin molecules consist of noncovalently associated ␣ and ␤ transmembrane polypeptide chains. Lymphocyte function-associated antigen-1 (LFA-1, ␣ L ␤ 2 or CD11a/CD18) represents the predominant integrin on lymphocytes. By binding to its major Ig superfamily (IgSF) ligand ICAM-1 (intercellular adhesion molecule-1), and to other ICAM family members, LFA-1 plays a vital role in adhesive interactions with both vascular endothelial cells and antigen-presenting cells (1-3). Integrin's activity is dynamically regulated by bidirectional transmembrane signaling. In lymphocytes, the ability of LFA-1 to bind ICAM-1 is rapidly upregulated in response to the intracellular signaling elicited by activation of other receptors, including chemokine and T cell receptors (inside-out signaling). Conversely, the binding of ICAM-1 to LFA-1 transmits signals to the cytoplasm, thereby altering gene expression and cellular metabolism (outside-in signaling) (4, 5) .
The ligand-binding domain of LFA-1, which has been designated an inserted (I) domain of approximately 200 amino acids (aa) in the ␣ L subunit, forms an independent Rossmann fold with a central ␤ sheet flanked by seven ␣ helices. A divalent ion is located at the upper side of the domain in a metal ion-dependent adhesion site (MIDAS) (6) , to which ICAM-1 binds. The C-terminal part of the I domain comprising the ␣7 helix and the preceding ␤6-␣7 loop is conformationally mobile, adopting three distinct conformations: closed, intermediate, and open. The wild-type, ICAM-1-unbound I domain possesses both the lowaffinity configuration of the MIDAS and the closed conformation of the C-terminal part. ICAM-1 binding to the MIDAS stabilizes its high-affinity configuration. This change at the MIDAS is linked to the downward shift of the I domain's ␣7 helix one to two helical turns and to the reshaping of the ␤6-␣7 loop, progressively inducing the intermediate and open conformations, respectively. The downward shift of the ␣7 helix would typically relay the outside-in conformational signals within the LFA-1 ecto-domain toward the cytoplasm. Conversely, insideout signals facilitate the induction of the downward shift of the I domain ␣7 helix, which is allosterically linked to the conversion of the MIDAS to the high-affinity configuration (5) . In this way, those conformational changes of the I domain involving an allosteric coupling of the MIDAS configuration and the conformation of the C-terminal part constitute an essential mechanism for transmitting bidirectional signals and integrin affinity regulation (7) . From energetic point of view, signaling molecules have population distribution among different conformational states on evolutionarily selected energy landscape. Stimulants from inside or outside cell will remodel this landscape and shift the population distribution, biasing toward a particular downstream functional event (8) .
Most antibodies against integrin I domains bind equally well to the alternative conformations. However, two known antibodies are activation-dependent and bind significantly better to the higher affinity conformation of the I domain. Mouse anti-human Mac-1 monoclonal antibody (mAb) CBRM1/5 binds only the active integrin Mac-1 (9). The epitope was mapped to the ␤1-␣1 loop, the ␣3 helix, and ␣3-␣4 loop in the activated form of the I domain (10) . More recently, AL-57 (activated LFA-1 clone 57), was selected by a phage display that targeted a mutationally stabilized HA domain, versus the default, wild-type LA LFA-1 I domain (11) . AL-57 functions as an ICAM-1 mimetic antibody that exhibits several key features of the ICAM-1/LFA-1 interaction. Not only do AL-57 and ICAM-1 both bind progressively better as LFA-1 affinity increases, they both require Mg 2ϩ for binding. However, certain underlying structural features remain unclear; e.g., how does AL-57 preferentially recognize the higher affinity I domain, and does AL-57 binding to the I domain compel a conversion to the open the conformation? Here, we describe crystal structures of the Fab fragment of the AL-57 in complex with LFA-1 I domain and of the Fab alone. The comparative studies we carried out reveal AL-57 as the only known ligand-mimetic mAb to LFA-1. The structures also explain AL-57's binding preference for the high affinity I domain conformation and how it competes against ICAM-1 binding.
Results and Discussion
The Overview. To understand the molecular mechanism of AL-57's activation-dependent binding and to see whether, like
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ICAM-1, the binding of AL-57 to the I domain forces its conversion to the higher-affinity I domain, we decided to co-crystallize AL-57 with the disulfide-stabilized IA I domain mutant (L161C/F299C). In the absence of bound ICAM-1, the IA I domain mutant (L161C/F299C) assumes the low-affinity MIDAS conformation, with the C-terminal ␣7 helix and ␤6-␣7 loop of the domain mutationally stabilized in the intermediate conformation (7) . However, in the complex structure of ICAM-1/IA, the MIDAS is converted to a high-affinity conformation and the C-terminal portion changes into an open conformation (7) . We wanted to see at an atomic level whether AL-57, as a ligand-mimetic, would favor these conformational changes as well.
Cocrystals in the space group P6 5 diffracted to 2.3 Å. The structure was determined using molecular replacement, locating two complexes in one asymmetric unit. There are no significant structural variations between the two independent AL-57/IA complexes. AL-57 Fab alone was crystallized in a distinct condition. The crystals are in space group P6 1 22 with one molecule per asymmetric unit and diffracted to 2.5 Å. The structure was similarly solved using molecular replacement. Table 1 gives the crystallographic data and the refinement statistics. Fig. 1 depicts two views of the C␣ trace of the AL-57/IA complex A (in green) with unligated AL-57 Fab (in orange) and an unligated intermediate affinity LFA-1 I domain (in pink) superimposed on the corresponding domains for comparison. In this figure, the AL-57 superposition is based upon the variable domains of the antibody, the Fv module. The constant module C L /C H1 showed a rigid-body approximately 8°rotation compared to the orientation in unbound AL-57. The most interesting change stemming from ligation was associated with the CDR3H loop of the heavy chain's variable domain V H . In the unligated AL-57 structure, the electron density for this loop was the poorest of all. The entire loop was less well ordered. The main chain of CDR3H loop can still be traced without ambiguity, and the loop appears to extend straight away from AL-57 (colored in purple in Fig. 1 ). However the side chains for the key integrinbinding residue Asp-101(H) and its neighboring Phe-102(H) were very mobile and difficult to define. Upon binding to IA, Asp-101(H) coordinated the metal ion on MIDAS, which brought the complete CDR3H loop into order and changed its conformation to bend toward the body of AL-57 (colored in red in AL-57 Preferentially Binds to the Affinity-Upregulated I Domain. The characteristic feature of LFA-1's authentic ligands, namely ICAM-1 and the other ICAM family members, is that they preferentially bind to the affinity-upregulated I domain (12). Numbers in parentheses are for the highest resolution shell. Rsym ϭ ͚ hkl͉I-͗I͉͘/͚I, where I is the observed intensity and ͗I͘ is the average intensity from observations of symmetry-related reflections. A subset of the data (5%) was excluded from the refinement and used to calculate R free. R ϭ ͚͉͉F o͉-͉Fc͉͉/͚͉Fo͉. This is a tendency also shared by the AL-57 antibody. Both a cell-binding assay (13) and surface plasmon resonance (SPR) analysis (11) showed that the monoclonal antibody AL-57 discriminates among wild-type low-affinity LA, mutationallystabilized intermediate-affinity IA, and mutatationallystabilized high-affinity HA states of LFA-1. With SPR, AL-57 showed no binding to LA domain, but binding to IA and HA domains with K D being approximately 4.7 M and 0.023 M, respectively (11) . The binding preference of AL-57 has now been demonstrated by comparative structural studies. Early structural data have shown that ICAM family members share the same binding mode to the LFA-1 I domain (7, 14, 15) . Central in the binding site is an invariant acidic residue designated Glu-37 (the residue numbering follows ICAM-3's nomenclature throughout) coordinating to the MIDAS metal ion. With the wild-type or unligated intermediate affinity IA I domain, the MIDAS was in a closed conformation (Fig. 2C) , wherein one acidic MIDAS residue (Asp-239) directly coordinated the metal, along with Ser-139 and Ser-141 on the ␤1-␣1 loop. Another MIDAS residue (Thr-206) bound to the metal indirectly via a water molecule. There was one additional water molecule that completed the coordination geometry. By contrast, ligation stabilized the geometry of MIDAS in an open conformation (Fig. 2B , from ICAM-3/HA structure). In the open conformation, the acidic residue Asp-239 moved away into the secondary coordination sphere. Since an acidic I domain residue no longer directly coordinates the metal, this altered metal coordination most likely strengthens the interaction between the metal ion and the acidic residue from the ligand. In this case, it is the ligand that donates the only negatively charged oxygen to the primary coordination sphere. Again, there was one additional water molecule completing the coordination geometry. Ligandbinding was also accompanied by a 2.3 Å ''sideways'' movement of the metal ion (5). Interestingly, upon AL-57 binding to the I domain, the acidic residue Asp-101 from AL-57's CDR3H loop played the same role as Glu-37 of ICAM did. In the AL-57/IA structure (Fig. 2 A) , this Asp-101(H) completes the octahedral coordination geometry of the metal in IA's MIDAS. Thus, the direct coordination of an acidic residue to the MIDAS of the I domain in an open conformation is a key structural feature shared by the authentic ligand and AL-57. Furthermore, other coordinating MIDAS residues also slightly shift in the same direction for AL-57/IA and ICAM-1/IA structures, compared to those MIDAS residues in the closed conformation.
Another hallmark structural alteration from the closed to the open conformation of the I domain upon AL-57 or ICAM binding is that a conserved Gly-240 in the ␤4-␣5 loop of I domain flips its main chain conformation such that the ␤4-␣5 loop bends away from the binding surface. This flipping of Gly-240 is coupled to the movement of the immediately neighboring Asp-239, which pulls this MIDAS coordinating residue away from any direct coordination to the metal, as discussed above. Consequently, the flipping movement also leads to the reorientation of the downstream neighboring Glu-241 into a favorable position, enabling a crucial electrostatic interaction to the basic residue Lys-42 from ligand ICAM-3 (or Lys-39 in ICAM-1 and Arg-42 in ICAM-5) (7, 14, 15) . In the current AL-57/IA structure, there occurred a similar interaction between Glu-241 and AL-57's Arg-31(H) (Fig. 3A) . It is noteworthy that this main chain flipping can only occur when a Gly occupies the I domain's position 240 as a conserved residue (3). Apparently, the concerted movement of Asp-239-Gly-240-Glu-241, located on the ␤4-␣5 loop, one of the MIDAS loops, is characteristic of allosteric conformational changes to the I domain upon ligandbinding. Thus, the AL-57/IA structure revealed two key features, which AL-57 shares with ICAMs, supporting preferential binding to the affinity-upregulated I domain: Asp-101 on CDR3H, which directly coordinates to the open MIDAS configuration; and Arg-31 on CDR1H, which forms an electrostatic interaction with Glu-241 in the open conformation.
In contrast to the above discussion on Asp-101(H) and Arg-31(H), residue Trp-103 in the flexible CDR3H loop of AL-57 plays a unique role in favoring binding to the affinityupregulated I domain, which is observed only in AL-57 and not in ICAM. Trp-103(H) formed a hydrogen bond from its indole ring to the carboxyl group of Asp-239 on the ␣ L ␤4-␣5 loop (Fig.  4) . In turn, this MIDAS residue Asp-239 indirectly bound to the metal via a water molecule (Fig. 2 A and Fig. 4) . In this way, binding to ligand orients the side chain of Trp-103(H) in AL-57. Compared with the wild-type closed conformation LA I domain, both the ␤5-␣6 and ␤6-␣7 loops of the open conformation moved downward in the direction indicated by the arrows in Fig. 4 . Consequently, His-264 on the ␤5-␣6 loop had its imidazole ring snugly sandwiched between Trp-103(H) and Trp-52(H) of AL-57. By contrast, the wild-type LA was in a closed conformation with the ␤5-␣6 loop closer to the MIDAS. Should the AL-57 antibody have approached LA domain, the side chain of His-264 would have collided with the Trp-103(H) (See Fig. 4 , a magentacolored His-264's sidechain clashes with Trp-103 of AL-57). This may explain why AL-57/LA binding is not detectable, further demonstrating AL-57's binding preference.
This begs the question: why does AL-57 bind in a stronger fashion to HA than to IA I domain? As mentioned before, AL-57 binding triggers IA domain to change its conformation to an open state, similar to HA, and to what was observed when ICAM-1 bound to IA domain (7). ICAM-1 binding to the MIDAS allosterically induced the reshaping of a remote ␤6-␣7 loop and the downward axial displacement of the C-terminal helix, thereby relaying outside-in conformational signaling toward the cytoplasm. Because of the strain imposed by the engineered disulfide bond between Cys-161 and Cys-299, the middle portion (where Cys-299 is located) of the IA's C-terminal helix ␣7 has been restrained. This makes the ␣7 helix end at Gln-303, as opposed to Ile-306 in unligated IA. All of these factors cost energy and likely contribute to the relatively low affinity of the AL-57/IA interaction, compared to that of the AL-57/HA interaction.
The Uniqueness of AL-57 Among Antibodies to Integrin I Domains. The direct metal coordination from an acidic residue and the induced concerted movement of Asp-239-Gly-240-Glu-241 on I domain's ␤4-␣5 loop discussed above revealed the ligand-mimetic features of AL-57 when it binds to the LFA-1 I domain. Moreover, AL-57 is not only ligand-mimetic, but also binds with higher affinity than the native ligand. SPR measurements have shown that the affinity of AL-57 binding to the high-affinity I domain of LFA-1 is about 6-fold higher than that of ICAM-1 binding. In particular, the off-rate for AL-57 binding is 0.0055 s Ϫ1 ϫ 10 2 , as opposed to 1.4 s Ϫ1 ϫ 10 2 for ICAM-1 binding; in other words, more than 250-fold slower for AL-57-binding than for ICAM-1-binding (11) . The buried surface area of the AL-57/IA complex is 1864 Å 2 , which is slightly higher than average value of 1,680 Å compared with other antibody/antigen values (16) . However, the interface's shape complementary index (Sc value) is 0.78, sig- 4 . Conformational changes to the I domain in AL-57/IA compared to the wild-type low-affinity I domain (LA, PDB code 1LFA). LA was superimposed onto the IA in the AL-57/IA complex. These structures are shown as C␣ traces with AL-57 and IA in green and LA in pink. Three residues from AL-57 (D101, W103, and W52) and two residues (D239 and H264) from IA were colored with green carbons and shown as stick models. Residue H264 from LA was colored with magenta carbons and shown as a stick model. The metal ion and a water molecule from IA were shown as a purple and red sphere, respectively. The hydrogen bonds from D239 of IA to W103 of Fab and a water molecule, as well as the coordination bonds between the metal ion and Fab's D101 are shown in yellow dash lines. Conformational changes of IA compared to those of LA in the ␤5-␣6 and ␤6-␣7 loops are indicated by black arrows. H264 in IA moved away from the MIDAS compared to H264 in LA.
nificantly higher than the average antibody/antigen value of 0.66 (17) , and is indicative of an excellent fit between AL-57 and IA domain in the complex. Notably, the buried surface area of ICAM-1/IA complex is only 1,250 Å 2 (7), much smaller than that of AL-57/IA. Its Sc value is 0.73, also lower than that of AL-57/IA. Furthermore, the AL-57/IA interface displays a remarkable cluster of aromatic residues from AL-57 (Fig. 3A) . These include Trp-52 of CDR2H, Tyr-100, Phe-102, and Trp-103 of CDR3H, as well as Tyr-32 of CDR1L and Tyr-92 of CDR3L. This kind of hydrophobic cluster is not seen in the interface between ICAMs and the I domain (14, 15) . The highly hydrophobic nature of the AL-57 interface clearly explains the 250-fold slower off-rate of AL-57 binding to the high-affinity ␣ L I domain compared to that observed in ICAM-1 binding, as demonstrated in our comparative binding studies on ICAM-1 and ICAM-3 (14) . Overall, such highly favored interface and binding kinetics strongly suggest that AL-57 acts as a ligand-mimetic that is strongly competitive with the native ligand.
An earlier report systematically studied the binding sites of numerous mAbs characterized to bind the ␣ L I domain (18) . Notably, none of these mAbs recognized species specific residues bound by ICAM-1, or were metal ion-dependent. The mAb were classed as competitive antagonists if they inhibited binding by both wild-type activated LFA-1 and HA LFA-1, and allosteric antagonists if they inhibited binding by wild-type activated LFA-1 but not HA LFA-1 (19, 20) . All competitive mAb bound near the ICAM binding site, and one agonistic mAb bound distant from this site. All mAb recognizing epitopes in the first residue of the ␣1-helix and in the ␣3-␣4 loop, which are adjacent in the structure and show little conformational movement, were competitive antagonists. In contrast, among mAb that bound to a group of seven adjacent residues in the ␤5-␣6 loop and ␣6-helix, which show substantially more conformational movement, one mAb was a competitive antagonist and two were allosteric antagonists (18) .
The mAb CBRM1/5 selectively recognizes the high affinity conformation of the ␣ M I domain (9) . However, binding does not require metal ion. Furthermore, mapping of the CBRM1/5 epitope shows it binds to the ␤1-␣1 loop and the ␣3 helix and ␣3-␣4 loop (10) . The residues in the epitope are in a conformationally mobile region on one side only of the MIDAS. These results suggest that the epitope does not include the MIDAS.
There is one structural report of mAb binding to the MIDAS of the I domain from a different integrin. This is the inhibitory monoclonal antibody AQC2, which acts against the I domain of ␣ 1 ␤ 1 integrin (21) . Despite containing an acidic residue from AQC2 binding to the metal ion on MIDAS, in a fashion similar to that of a natural ligand, the I domain remains in the closed form. This is intriguing. A close examination demonstrates that the important Asp-257-G258-Glu-259 motif on the ␤4-␣5 loop of ␣ 1 I domain is, indeed, in a closed conformation. One key fact is that the Glu-259 of the ␣ 1 I domain, the counterpart to Glu-241 of the ␣ L I domain discussed above, does not have its crucial salt bridge partner from AQC2 to thus consolidate the binding. The main chain conformation of Gly-258 does not f lip so that the ␤4-␣5 loop still keeps pointing upwards like that in the unligated I domain. There is no water molecule to bridge the interaction between the metal and Asp-257, as is commonly seen in the open conformation, which further confirms the closed conformation status of AQC2. Therefore, AQC2 is not a ligand-mimetic. It binds closed conformation of I domain, and exerts its inhibitory effect via sterically blocking ligand-binding to the ␣ 1 I domain.
A very recent report describes a structure of LFA-1 I domain in complex with the Fab portion of humanized monoclonal IgG 1 antibody, Efalizumab, which is clinically approved drug for treating patients with psoriasis (22) . In that structure, Fab binds to the side of the I domain on the ␣1 and ␣3 helices, i.e., to the same epitope as one group of previously mapped competitive antagonist mAbs (18) . As the binding does not trigger any conformational changes, the I domain remains in a closed, low-affinity conformation. The most interesting aspect of this structure is that the Efalizumab epitope on the LFA-1 I domain does not overlap with the ICAM-1-binding region per se. Instead, the drug's inhibitory effect stems from the steric hindrance between the antibody's light chain and the ICAM-1 domain 2.
The conclusion from our AL-57/IA complex structure studies is that AL-57 represents an example of a monoclonal antibody that binds to the ␣ L I domain in a ligand-mimetic fashion, and which discriminatively acts upon the affinity-upregulated I domain. This contrasts with the clinically approved mAb to LFA-1, which binds to the closed conformation of I domain and sterically blocks ligand-binding. An mAb like AL-57 may have favorable pharmacokinetics with long half-life in vivo, and have fewer potential side effects (13) .
The unique features of AL-57 may in part derive from the fact that it was isolated from an artificial, human-like antibody library displayed in phage (17) . Thus, it has not been negatively selected against self, as are natural antibodies. Natural antibodies recognize species-specific differences. The species-specific residues in LFA-1 that are in ICAM contact regions and recognized by mAb have previously been compared (18) . Although speciesspecific residues are present in the ICAM contact region, they appear to be scarcer than in the epitopes recognized by an extensively mapped subset of antibodies. The uniqueness of AL-57 may also in part be attributable to the strong selection against the low affinity conformation and for the high affinity conformation during its isolation. The structural studies reported here suggest that it should in principle be possible to obtain antibodies that faithfully mimic highly conformationallyspecific biological interactions, for a wide range of biological and pharmaceutical applications.
Methods
Protein Production and Crystallization. The ␣L IA domain was expressed in E. coli, refolded, and purified as previously described (7). The IA protein was concentrated and exchanged into a buffer containing 10 mM HEPES pH 7.5, 50 mM sodium chloride, and 5 mM manganese chloride. A Fab fragment of antibody AL-57 was prepared as described (11) . Crystals were obtained using hanging droplet vapor diffusion. One microliter of Fab at 20 mg/mL was mixed with 1 L of reservoir buffer in 0.1 M cacodylate pH 6.4, 0.2 M Zn(Ac)2, 18% PEG8000. The cryoprotectant for crystals of Fab alone is 0.1 M cacodylate pH 6.4, 20% glycerol and 30% PEG8000. One microliter of an equal molar mixture of Fab and IA at a total concentration of 18 mg/mL was mixed with 1 L of reservoir buffer in 0.1 M sodium acetate, pH 5.5, 2.0 M (NH 4)2SO4. The cryoprotectant for the complex crystals is 0.1 M sodium acetate, pH 5.5, 2.0 M (NH4)2SO4, 0.3 M sodium citrate.
Structure Determination. Crystals were harvested and soaked in the cryoprotectant and then flash frozen into liquid nitrogen. The diffraction data were collected using the beamline 19ID at Argonne National Laboratory and processed with HKL2000 (23). Molecular replacement was performed to determine the structure using the program Phaser from CCP4 (24) . IA domain from the complex of ICAM1-IA (PDB code 1MQ8) and the Fab fragment from PDB 1MHP (the structure of the ␣1 I domain in complex with Fab) were used as the search model. The variable region of Fab (with CDR loops deleted) was used as the first search model, IA domain as the second, and the constant region of Fab as the last search model. The complex was refined with Refmac and cycled with model rebuilding using Coot (25) . TLS refinement was incorporated into the later stages of the refinement process. The final model was analyzed with MolProbity (26) . The coordinates of the Fab alone, and in complex with IA, have been deposited in the Protein Data Bank with the codes 3HI5 and 3HI6, respectively.
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